Researcher Received Grant for Psilocybin Addiction Study
A Roanoke doctor secured federal funding to test psilocybin as a treatment for cocaine addiction.
Updated on Sept. 23, 2026 in Substance Abuse
Live Poll
Should federal agencies prioritize funding for research into psychedelic treatments for drug addiction?
Dr. Albert Arias has received a $623,000 federal grant to conduct a pilot study using psilocybin and psychotherapy to treat cocaine addiction. The research aims to evaluate if the substance can help patients unlearn addictive behaviors.
Why it matters
Currently, there is no federally approved medication for treating cocaine addiction. Researchers hypothesize that psilocybin may enhance neuroplasticity, potentially offering a new therapeutic pathway for patients.
The pilot study includes 27 participants receiving either 5, 25, or 40 milligrams of psilocybin over six weeks. This initial grant of $623,000 may expand to $3.5 million pending future funding allocations.
The players
Dr. Albert Arias
He is the lead researcher based in Roanoke who is spearheading the psilocybin study.
National Institute on Drug Abuse
This federal agency is responsible for providing the funding for drug addiction research.
Donald Trump
He is the current President of the United States who signed an executive order to accelerate psychedelic research.
The details
The study uses a 5-milligram dose as an active placebo to mask the psychedelic effects and ensure objective results. Researchers will monitor how psilocybin affects cravings and usage patterns alongside traditional psychotherapy sessions.
Timeline
President Donald Trump signed an executive order on psychedelic research in April 2026.
Virginia passed Senate Bill 379 regarding psilocybin rescheduling in 2026.
Health Landscape
This study reflects a growing shift in federal policy toward evaluating the therapeutic potential of previously prohibited substances. It contrasts with the historical limitations of the Controlled Substances Act, which currently classifies psilocybin as a Schedule I drug.
While this pilot is limited to 27 participants, it could eventually lead to new, FDA-approved treatment options for those struggling with cocaine addiction. Patients should note that psilocybin remains a Schedule I controlled substance outside of authorized research settings.
The takeaway
The federal move to fund psychedelic research signals a major transition in how clinical science approaches treatment-resistant addictions. Participants and patients should stay informed as future phases of this study may expand the availability of these experimental therapies.
Further reading
Learn more about the latest research in the Substance Abuse section.
Source note: This article includes information reported by Cardinal News.
Live Poll
Should federal agencies prioritize funding for research into psychedelic treatments for drug addiction?
